The Bage Family

Exploits of two crazy kids, and two long suffering parents.

[The Bage Family @bage_t]

@mpay25 @Han_Akamatsu On all social media. The idea that you could buy a country estate etc. off the back of a single share trade is laughable.

[bluefinsashimi @bluefinsashimi]

BREAKING!!! $IBRX The European Commission's Implementing Decision (C(2026)1197) is the final, binding step granting **conditional marketing authorization** for ANKTIVA (nogapendekin alfa inbakicept) + BCG in the EU. This follows the EMA/CHMP positive opinion from December 2025 and allows ImmunityBio ($IBRX) to market the therapy across the 27 EU member states (plus Iceland, Norway, Liechtenstein) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. It's a major milestone: ANKTIVA becomes the first immunotherapy approved in Europe for this indication, addressing a clear unmet need where options were limited to radical cystectomy (bladder removal). Conditional status means ongoing data collection/post-approval studies, but it enables early patient access and commercial launch planning in a market with over 150,000 annual NMIBC diagnoses. For $IBRX, this expands ANKTIVA beyond US/UK/Saudi approvals, diversifying revenue potential and validating the IL-15 platform globally. While not a surprise (EC approvals after CHMP positive opinions are routine), the official publication confirms execution and removes any remaining regulatory overhang for this indication in Europe.

Link to the decision: https://t.co/GSaYwifhkN $IBRX

@DrPatrick @DrMakaryFDA @SecKennedy #BioShield #Anktiva

[Billions777888 @Billions777888]

$IBRX to the MOON! Next stop $15-$20!

[Essex Trading 🐢 @essextrading]

$IBRX Bull flag breakout

[Antonio Costa @ACInvestorBlog]

$SMX Big breakout on volume expansion

[JTrading_ProTips @JTrades_Pro]

🗞️

$SMX 11:55 on Feb. 06 2026

SMX Extends Its Capital Runway Into 2028, ELOC Agreement Increased to $250 Million

[Dr. Pat Soon-Shiong @DrPatrick]

Sorry about the confusion that came from “ medical scientific speak” in our press release on Friday! Folks read that as if patients failed to survive when the release meant the opposite!
The “Median 0verall survival “ is a scientific and standard endpoint used to measure survival and currently about 6 or so months is that mark sadly in these patients with brain tumors..meaning that 50percent of patients at this stage do not survive beyond this time frame of 6 months and longer. The fact that we have patients alive still at 12 months and that the “median has NOT YET been reached “ IS a positive and promising finding to date with our chemo free treatment in which patients have failed current standards of care.
Thanks for clarifying for all
Perhaps I should begin my “ Conversations” podcast soon so that I explain better rather than the statistical analysis speak!

[Carter Vance📚 @SeanDanielsLive]

$KUST surged to $2.76 (+35%).

Commercial services lag sometimes, but when they go, they go. The chart shows a clean cup and handle breakout.

I want to see a hold above $2.60 into the close. Weakness there kills the momentum.

Tracking: $CHRS $LIF $GIBO $BA $LMT

[NOTRELOAD AI @notreload_ai]

$CHRS +3.8% [Oppenheimer initiates coverage of Coherus Oncology with an Outperform rating and a $10 price target, highlighting promising cancer drug programs and key clinical data expected in 2026.] https://t.co/ZQlhRwEcsP

[Benjamin Hernandez😎 @HayesStocks]

$CHRS at $2.06, up +29%.

Biotech is volatile, but the risk/reward here is skewed upside if $1.90 holds. The volume is confirming the breakout from the lows.

Lock in profits into strength. Don't let a green trade turn red.

On watch: $LIF $GIBO $RVYL $IBB $XBI

[Liam @phanie_delacr]

$CHRS THE $2.00 BARRIER.

We are up +23% at $1.96, knocking on the door of the psychological $2.00 level. Unlike the other runners today, this chart isn't exhausted yet.

The Technical Reality (1H Chart): Efficient Move: We rallied +23% on only 2.84% Turnover. This is highly efficient buying. Sellers are holding, not dumping. Room to Run (KDJ):

J-Line is at 62.05.

Most "runners" hit J > 100 before crashing. This implies the momentum engine is only in 3rd gear. There is plenty of gas left in the tank.

Band Walk: Price is holding comfortably above the Upper Bollinger Band ($1.75).

My Playbook:The $2.00 wall is the magnet.

The "Breakout" continuation (Primary):

Trigger: A clean break and hold above $2.00.

Target: Blue sky to $2.25 - $2.40.

Stop: $1.85.

The "Rejection" Fade (Scalp):

Logic: If $2.00 rejects 3 times (Triple Top).

Entry: Short near $1.98.

Target: Back to the Upper Band at $1.75.

I'm posting the $2.00 breakout alert live in the private chat. Get the entry signal. Add the WhatsApp: [https://t.co/eXKHoEn9L4]

#CHRS #Biotech #Breakout #Trading #Stocks #Pharma #StockMarket

[Jones investment📈📊💎 @jonestockwatch]

$CHRS $1,80 🚀 Today +$2 💎💎💎💎

[The Bage Family @bage_t]

@Jeff_Beach NO LONGER a "speculative" buy - it's an aggressive value play with improving technicals at a confirmed bottoming zone. The extreme oversold RSI, 3-month MACD buy signal, multiple reversal patterns, and fundamental asset backing create a compelling risk/reward setup.

[Bryan Harkins @UMiLiveOfficial]

🔥 Today's Recommendation: $GPUS

It has been waiting for a breakout opportunity, having been consolidating for a long time. Today should bring a qualitative change.

Reason for recommendation: Strong short-term breakout, bullish technical outlook.

[Omar El Zoghby @MrElzoghbyTrade]

$GPUS is a 1000% runner from my entry point
But for now I’m expecting 0.72$

[The Bage Family @bage_t]

$gpus - Revenue projections for Hyperscale Data:

At 30 MW (current): ~$56 million annually (proportional to Applied Digital benchmark)

At 70 MW (20-month target): ~$131 million annually

At 340 MW (full buildout): ~$635 million annually

[The Bage Family @bage_t]

@MrMikeInvesting You only get generational wealth in the UK, France, Spain and Portugal.

[The Bage Family @bage_t]

@MarioNawfal Even more socially isolated now.

[The Bage Family @bage_t]

@TrumpsHurricane Because I don't live in Swansea